OnCo
ideasIdea

Geriatric assessment by default for every older patient, and trials that admit them

Most cancer patients are over 65, yet treatment is chosen by age and guesswork and trials exclude them. Assess fitness properly and design trials that include real older patients.

Geriatric assessment-guided management reduced serious toxicity without compromising survival in randomised trials (GAP70+, GAIN). Uptake remains low and trial populations are far younger and fitter than practice. The proposal is a default assessment (short validated screen with full assessment when triggered) embedded in the record for all patients over 70 starting systemic therapy, payment for the assessment, and a requirement from regulators and funders that pivotal trials include older and comorbid patients in proportion to the treated population, with pre-specified analyses.

Hypothesis
Default assessment reduces grade 3+ toxicity in older patients by a fifth, and trial populations shift within five years to include older patients in proportion to disease incidence.
Rationale
Chronological age is a poor guide to tolerance; assessment tools are validated and quick, and trial exclusion is a habit rather than a scientific necessity.
What would test it
Roll out across a health system with toxicity and treatment completion as endpoints, and audit the age distribution in pivotal trials before and after the requirement.
Maturity
being tested at scale
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks

Key papers

1top

Connected

5top

Pages like this

not linked directly; found by shared links